Skip Navigation

Annals of Oncology 2008 19(2):203-204; doi:10.1093/annonc/mdm603
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Huddart, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huddart, R. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2008 European Society for Medical Oncology. For Permissions, please email: journals.permissions@oxfordjournals.org

editorials

The management of non-seminomatous germ-cell tumours patients with viable malignancy at the time of RPLND

R. A. Huddart

Institute of Cancer Research and Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK

(E-mail: robert.huddart@icr.ac.uk)

The first 10% of the full text of this article appears below.

What should I do if my first-line chemotherapy has not irradicated all active germ-cell tumour (GCT)? This is the clinical conundrum addressed by Fizazi et al. [1] in this issue of Annals of Oncology, an area of controversy but not a lot of light.

Standard therapy for patients with metastatic non-seminomatous germ-cell tumours remains the use of combination cisplatin-based chemotherapy with the current standard of care being three or four cycles of bleomycin, etoposide and cisplatin (BEP) chemotherapy depending on the prognostic category [2–4]. The majority of patients are cured by such therapy with long-term survival expected in >90% [3–5] except for the minority with poor prognosis disease. Approximately, a third of these patients, however, will be left with residual masses over 1–2 cm for which surgery is advised . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?